Literature DB >> 17804301

Effects of angiotensin II on human endothelial cells survival signalling pathways and its angiogenic response.

Baijun Kou1, Manu Vatish, Donald R J Singer.   

Abstract

Reduced capillary density (rarefaction) is an early event of cardiovascular disease. The PI-3K-Akt pathway is a key player in anti-endothelial cells (ECs) apoptosis. VEGF is a key growth factor for angiogenesis. We investigated the effect of Angiotensin II (Ang II) on ECs survival signalling and angiogenesis in vitro. We found that Ang II had a biphasic effect on Akt phosphorylation by western blotting analysis. Low concentration Ang II caused a dose-dependent increase in Akt phosphorylation, while high concentration of Ang II led to a decrease of Akt phosphorylation. This effect was negative regulated by its type II receptor. Ang II 10(-4) M induced ECs apoptosis by its type II receptor was completely blocked by VEGF. Cell viability was increased by Ang II 10(-6) M and decreased by Ang II 10(-4) M. It was further decreased by pre-treatment with PI-3K/Akt inhibitor LY294002, but unaffected by p38-MAPK inhibitor SB202190. Ang II 10(-4) M reduced ECs' proliferation and vascular tube length, which were in part regulated by type II receptor. Our findings support a dose-dependent role of Ang II in effect on ECs survival and angiogenesis by PI-3K/Akt pathway. The anti-angiogenic effect of Ang II was mediated by its type II receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804301     DOI: 10.1016/j.vph.2007.06.011

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  6 in total

1.  Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.

Authors:  Cuneyt K Buharalioglu; Chi Young Song; Fariborz A Yaghini; Hafiz U B Ghafoor; Mustafa Motiwala; Tusita Adris; Anne M Estes; Kafait U Malik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-03       Impact factor: 4.733

2.  Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II.

Authors:  Haiming Dang; Bangrong Song; Ran Dong; Hongjia Zhang
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

3.  AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

Authors:  Ahmed Alhusban; Anna Kozak; Adviye Ergul; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

4.  Impact of AT2 receptor deficiency on postnatal cardiovascular development.

Authors:  Daniel Biermann; Andreas Heilmann; Michael Didié; Saskia Schlossarek; Azadeh Wahab; Michael Grimm; Maria Römer; Hermann Reichenspurner; Karim R Sultan; Anna Steenpass; Süleyman Ergün; Sonia Donzelli; Lucie Carrier; Heimo Ehmke; Wolfram H Zimmermann; Lutz Hein; Rainer H Böger; Ralf A Benndorf
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

5.  Disparate biomechanical properties of the aorta in non-aneurysmal and aneurysmal mice treated with angiotensin II.

Authors:  Sofie De Moudt; Jhana O Hendrickx; Guido R Y De Meyer; Wim Martinet; Paul Fransen
Journal:  Physiol Rep       Date:  2022-09

Review 6.  Clinical Perspectives on Targeting Therapies for Personalized Medicine.

Authors:  Donald R J Singer; Zoulikha M Zaïr
Journal:  Adv Protein Chem Struct Biol       Date:  2015-12-29       Impact factor: 3.507

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.